T3 Level 463 467 cell
T4 Level 850 854 cell
T6 Level 635 646  Th17 cells
T8 Level 791 796 cells
T9 Condition 966 971 tumor
T11 Level 641 645 cell
T12 Level 76 83 T cells
T14 Organism 129 137 patients
T15 Level 1173 1178 cells
T16 Level 367 377 Th17 cells
T18 Level 1173 1177 cell
T19 Level 358 365 T cells
T23 Level 277 281 cell
T24 Level 592 596 cell
T25 Species 956 960 mice
T27 Level 225 229 cell
T28 Level 451 455 cell
T29 Level 360 364 cell
T30 Level 1234 1238 cell
T31 Level 1257 1261 cell
T32 Condition 755 760 tumor
T33 Level 791 795 cell
T37 Condition 1138 1156 human mesothelioma
T39 Level 1214 1239 tumor-reactive Th17 cells
T40 Level 567 597 Three-week-expanded Th17 cells
T41 Condition 106 115 antitumor
T43 Condition 1274 1280 cancer
T44 Condition 742 761 recalcitrant tumors
T45 Level 457 468  Th17 cells
T47 Condition 27 39 solid tumors
T48 Level 451 456 cells
T49 Level 1087 1098  Th17 cells
T51 Condition 609 617 melanoma
T53 Level 223 230 T cells
T54 Condition 1214 1219 tumor
T55 Level 1093 1097 cell
T57 Condition 539 548 antitumor
T58 Level 78 82 cell
T60 Level 1024 1081 2-week-expanded human chimeric antigen receptorâ€“positive 
T61 Level 372 376 cell
T62 Species 702 706 mice
T63 Condition 33 38 tumor
T64 Level 935 939 cell
T65 Intervention 994 998 lung
T66 Level 911 940 Long-term-expanded Th17 cells
T67 Species 726 730 mice
R1 Relation Arg1:T27 Arg2:T23
R2 Relation Arg1:T53 Arg2:T23
R3 Relation Arg1:T27 Arg2:T53
